iifl-logo-icon 1

Anus Laboratories Ltd Share Price

0.24
(0.00%)
Mar 16, 2015|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Anus Laboratories Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

0.23

Prev. Close

0.24

Turnover(Lac.)

0.54

Day's High

0.25

Day's Low

0.23

52 Week's High

0

52 Week's Low

0

Book Value

6.3

Face Value

1

Mkt Cap (₹ Cr.)

5.87

P/E

0

EPS

0

Divi. Yield

0

Anus Laboratories Ltd Corporate Action

No Record Found

Anus Laboratories Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Anus Laboratories Ltd SHAREHOLDING SNAPSHOT

05 Oct, 2024|08:47 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 39.30%

Foreign: 0.00%

Indian: 39.30%

Non-Promoter- 0.80%

Institutions: 0.79%

Non-Institutions: 59.90%

Custodian: 0.00%

Share Price

Anus Laboratories Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2012Mar-2011Mar-2010Mar-2009

Equity Capital

24.45

24.45

24.15

12.08

Preference Capital

0

0

0

0

Reserves

140.97

137.53

136.88

133.83

Net Worth

165.42

161.98

161.03

145.91

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2012Mar-2011

Revenue

268.04

272.66

yoy growth (%)

-1.69

Raw materials

-179.16

-180.06

As % of sales

66.84

66.03

Employee costs

-11.99

-10.29

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2012Mar-2011

Profit before tax

6.9

25.15

Depreciation

-7.67

-4.45

Tax paid

-2.9

-7.85

Working capital

19.82

Other operating items

View Cash Flow
Y/e 31 MarMar-2012Mar-2011

Growth matrix (%)

Revenue growth

-1.69

Op profit growth

-14.22

EBIT growth

-22.21

Net profit growth

-73.92

View Ratios
Particulars (Rupees in Crores.)Mar-2008

Gross Sales

168.3

Excise Duty

16.94

Net Sales

151.36

Other Operating Income

0

Other Income

3.02

Anus Laboratories Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,910.5

164.974,59,136.74237.820.714,409.7498.75

Divis Laboratories Ltd

DIVISLAB

5,422.55

86.761,44,114.934300.552,063507.93

Cipla Ltd

CIPLA

1,622.85

33.671,33,733.091,055.940.783,752.25346.39

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,475.6

76.341,14,734.624690.832,394201.77

Dr Reddys Laboratories Ltd

DRREDDY

6,635.5

27.281,12,386.621,417.20.595,823.91,458.55

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Anus Laboratories Ltd

Management

Register Office

Registrar Office

Managing Director

K Hari Babu

Whole-time Director

M S S V Satyanarayana

Company Secretary

Vidya Sagar Soma

Director

A Siva Rami Reddy

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

The Company was incorporated in the year 1996 for manufacture of Bulk Active Pharma Ingredients and Intermediates for drug molecules and was promoted by Mr. K. Hari Babu. Mr. N.S. Walimbe joined as co-promoter in the year 1997.The Company was not having its own manufacturing facilities initially and utilized premises and production facilities of Dr. Curies Labs Limited for a period of two years till 1998 under leave and license agreement, which terminated in September, 1998. At this facility the Company has manufactured 2,4 Dichloro 5 Fluoro Acetophenone (DCFA) a drug intermediate for manufacture of Quinolones, which has supplied to Dr. Reddys Laboratories Limited and Aurobindo Pharma Limited.The company has engaged in manufacture of Basic & Advanced Intermediates and fine chemicals and are presently having manufacturing facilities for key intermediates like 2,4-Dichloro-5-Fluoro Acetophenone (DCFA) (an intermediate for synthesizing quinolone antibiotics like ciprofloxacin); Chlorohexanone (key intermediate in the manufacture of cardio vascular medicine) and Methyl-4 (4-Chloro 1 oxo butane) a, a Di-Methyl Acetate (an intermediate in the manufacture of Fexofenadine an anti allergic drug). In July 14, 1998, The company entered an agreement with Andhra Pradesh Industrial Development Corporation (APIDC) and Andhra Pradesh State Financial Corporation (APSFC) to purchase land, buildings and plant & machinery of M/s Jay Organics Limited situated at Survey No. 17, Chilakamarri Villag
Read More

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS

  • Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020
  • Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange’s Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • Check your Securities / MF / Bonds in the consolidated account statement issued by NSDL/CDSL every month.
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day.” – Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets – once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp